Skip to main content
Evidence Snapshot

Tyrosine-protein kinase Yes

CHEMBL2073 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2073
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Yes as ChEMBL target CHEMBL2073, mapped to UniProt P07947. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Yes
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2073
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P07947
Tyrosine-protein kinase Yes
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase Yes matters

As of 2026-09-14

Tyrosine-protein kinase Yes is reviewed as Tyrosine-protein kinase Yes (UniProt P07947); Tyrosine-protein kinase Yes shows clinical signal disease relevance led by cancer.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 26 approved drugs, 1799 compounds, and 496 assays, with lead potency reaching pChEMBL 9.5.

Disease context
cancer

Tyrosine-protein kinase Yes shows clinical signal disease relevance led by cancer. 1 linked drug keep the rationale reviewable. Linked drugs include JNJ-26483327.

Start review with cancer because it currently carries clinical signal support. Linked drugs include JNJ-26483327. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 26 approved drugs, 1799 compounds, and 496 assays for this target. The dominant activity type is KD. CHEMBL400402 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL400402 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
26 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase Yes matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07947, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1799
Total Compounds
496
Total Assays
26
Approved Drugs
IC50: 283.0, KI: 18.0, KD: 393.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL400402
 9.5 IC50 —
No preferred name
CHEMBL5416410
 9.5 Kd Approved
No preferred name
CHEMBL5280844
 9.4 IC50 —
No preferred name
CHEMBL288441
 9.4 IC50 Approved
No preferred name
CHEMBL5416410
 9.3 IC50 Approved

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
GILTERITINIB
CHEMBL3301622
 2018
BRIGATINIB
CHEMBL3545311
 2017
NERATINIB
CHEMBL180022
 2017
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
IBRUTINIB
CHEMBL1873475
 2013
BOSUTINIB
CHEMBL288441
 2012
PONATINIB
CHEMBL1171837
 2012
VANDETANIB
CHEMBL24828
 2011
CRIZOTINIB
CHEMBL601719
 2011
DASATINIB
CHEMBL5416410
 2006
DASATINIB ANHYDROUS
CHEMBL1421
 2006
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2073